Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Sep;65(9):881-91.
doi: 10.1902/jop.1994.65.9.881.

Bone grafting and guided bone regeneration for immediate dental implants in humans

Affiliations
Clinical Trial

Bone grafting and guided bone regeneration for immediate dental implants in humans

M E Gher et al. J Periodontol. 1994 Sep.

Abstract

This study evaluated bone regeneration and osseointegration of hydroxyapatite (HA) coated and titanium plasma sprayed (TPS) implants placed in sockets immediately after extraction in 36 adults, mean age 55.2 years (range 26 to 81 years). Twelve TPS and 10 HA-coated implants in 20 patients were grafted with demineralized freeze-dried bone allograft (DFDBA), covered with a barrier material, and the facial flap coronally positioned to attain primary closure (experimental). The remaining 11 TPS and 10 HA-coated implants were placed similarly, except that no DFDBA was used (control). Osseous structures were measured at the initial placement and 6-month re-entry surgeries. At the 6-month re-entry, all implants placed were clinically osseointegrated. Bone resorption at the most coronal socket crest was -1.53 mm for the grafted group and -1.59 mm for the control group. Crestal bone apposition of 1.39 mm was noted at the most apical socket crest (ASC) for the grafted group, whereas crestal resorption of -0.11 mm was noted in the ungrafted control group (P < 0.02). Bone fill from the base of the deepest osseous defect was 5.68 mm for the grafted group and 3.18 mm for the control group (P < 0.04). Complete resolution of osseous defects occurred at 15 of 22 sites in the grafted group and at 9 of 21 sites in the control group. Clinical exposure of the barrier material and a subsequent inflammatory response at 27 of 43 sites, requires removal of the material prior to the 6-month re-entry and was associated with significantly more bone loss at the ASC sites (P < 0.01). There was no significant difference for any of the parameters when comparing the TPS with the HA-coated implants.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources